LALPATHLAB.NS Profit & Loss
Dr. Lal Path Labs Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:45
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹2,016.90 Cr. | ₹2,226.60 Cr. | ₹2,461.40 Cr. | ₹2,762.90 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹41.70 Cr. | ₹69.20 Cr. | ₹93.40 Cr. | ₹101.30 Cr. | OtherIncome |
| Total Income | ₹2,058.60 Cr. | ₹2,295.80 Cr. | ₹2,554.80 Cr. | ₹2,864.20 Cr. | Income |
| Cost of Materials Consumed | ₹447.20 Cr. | ₹451.40 Cr. | ₹481.50 Cr. | ₹534.60 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹376.50 Cr. | ₹424.50 Cr. | ₹482.40 Cr. | ₹503.30 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹37.50 Cr. | ₹29.40 Cr. | ₹22.30 Cr. | ₹22.80 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹150.20 Cr. | ₹143.60 Cr. | ₹141.90 Cr. | ₹161.80 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹703.30 Cr. | ₹741.40 Cr. | ₹802.00 Cr. | ₹942.50 Cr. | OtherExpenses |
| Total Expenses | ₹1,714.70 Cr. | ₹1,790.30 Cr. | ₹1,930.10 Cr. | ₹2,165.00 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹343.90 Cr. | ₹505.50 Cr. | ₹624.70 Cr. | ₹699.20 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-30.10 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹343.90 Cr. | ₹505.50 Cr. | ₹624.70 Cr. | ₹669.10 Cr. | ProfitBeforeTax |
| Tax Expense | ₹102.80 Cr. | ₹143.20 Cr. | ₹132.50 Cr. | ₹159.30 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹241.10 Cr. | ₹362.30 Cr. | ₹492.20 Cr. | ₹509.80 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹238.90 Cr. | ₹357.70 Cr. | ₹487.10 Cr. | ₹504.80 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹28.82 | ₹43.05 | ₹58.48 | ₹30.24 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹28.74 | ₹42.98 | ₹58.40 | ₹30.20 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from LALPATHLAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).